Guatemala vs Hong Kong: The number of people with susceptibility test result for rifampicin
Guatemala
95.02
in 2021
Hong Kong
94.83
in 2021
Guatemala rank
51st
Hong Kong rank
52nd
The number of people with susceptibility test result for rifampicin over time
- Guatemala
- Hong Kong
How they compare
Guatemala currently reports 95.02 against 94.83 in Hong Kong, a difference of 0.19.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Hong Kong ahead.
Guatemala ranks 51st and Hong Kong ranks 52nd of 146 countries.
Hong Kong has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | Hong Kong | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 43.35 | 96.18 | 52.83 | Hong Kong |
| 2020s | 64.93 | 94.72 | 29.79 | Hong Kong |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Guatemala or Hong Kong?
- Guatemala, at 95.02 against 94.83 in Hong Kong as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Guatemala and Hong Kong?
- 0.19, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and Hong Kong?
- 5 years are reported by both, from 2017 to 2021.
- How do Guatemala and Hong Kong rank globally for the number of people with susceptibility test result for rifampicin?
- Guatemala ranks 51st and Hong Kong ranks 52nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.